Single‐Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End‐Stage Renal Disease Requiring Hemodialysis

Solriamfetol (JZP‐110), a selective dopamine and norepinephrine reuptake inhibitor with wake‐promoting effects, is renally excreted ∼90% unchanged within 48 hours. Effects of renal impairment and hemodialysis on the pharmacokinetics and safety of 75‐mg single‐dose solriamfetol were evaluated in adul...

Descripción completa

Detalles Bibliográficos
Autores principales: Zomorodi, Katie, Chen, Dan, Lee, Lawrence, Lasseter, Kenneth, Marbury, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Special Populations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6618134/
https://www.ncbi.nlm.nih.gov/pubmed/30865315
http://dx.doi.org/10.1002/jcph.1402

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6618134/
https://www.ncbi.nlm.nih.gov/pubmed/30865315
http://dx.doi.org/10.1002/jcph.1402

Ejemplares similares